N

    Natera Inc (NTRA)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $321.96
    -4.30 (-1.32%)

    Market Cap: $47.03B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(24/40)
    Avg Surprise
    +3.16%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.24
    Range$-0.61 - $0.13
    14 analysts
    EPS Revisions
    8
    0
    7d
    8
    1
    30d
    EPS Estimate Drift
    90d ago$-0.35-44.4%
    60d ago$-0.36-49.3%
    30d ago$-0.38-55.0%
    7d ago$-0.24+1.1%
    Current$-0.24
    Revenue Consensus
    $707M
    Range$677M - $720M
    19 analysts
    Dec 31, 2026
    EPS Consensus$-0.06
    Range$-0.69 - $0.70
    15 analysts
    Revenue Consensus
    $920M
    Range$902M - $938M
    21 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.06---
    Sep 26EST
    		-$-0.24---
    Jun 26
    		$-0.47$-0.47+0.00%Beat+36.5%
    Mar 26
    		$-0.60$-0.55-9.09%Miss-20.0%
    Dec 25
    		$0.35$-0.46+176.09%Beat+185.4%
    Sep 25
    		$-0.64$-0.35-82.86%Miss-146.2%
    Jun 25
    		$-0.74$-0.60-23.33%Miss-146.7%
    Mar 25
    		$-0.50$-0.66+24.24%Beat+10.7%
    Dec 24
    		$-0.41$-0.35-18.29%Miss+35.9%
    Sep 24
    		$-0.26N/A+55.93%Beat+72.6%
    Jun 24
    		$-0.30N/A+55.88%Beat+69.1%
    Mar 24
    		$-0.56$-0.71+21.13%Beat+54.5%
    Dec 23
    		$-0.64$-0.71+9.86%Beat+53.3%
    Sep 23
    		$-0.95$-0.97+2.06%Beat+24.0%
    Jun 23
    		$-0.97$-1.10+11.82%Beat+35.3%
    Mar 23
    		$-1.23$-1.16-6.03%Miss+15.2%
    Dec 22
    		$-1.37$-1.42+3.52%Beat+7.4%
    Sep 22
    		$-1.25$-1.44+13.19%Beat+23.3%
    Jun 22
    		$-1.50$-1.50+0.00%Beat-13.6%
    Mar 22
    		$-1.45$-1.52+4.61%Beat-95.9%
    Dec 21
    		$-1.48$-1.31-12.98%Miss-60.9%
    Sep 21
    		$-1.63$-1.33-22.56%Miss-126.4%
    Jun 21
    		$-1.32$-1.20-10.00%Miss-94.1%
    Mar 21
    		$-0.74$-1.03+28.16%Beat-64.4%
    Dec 20
    		$-0.92$-0.62-48.39%Miss-109.1%
    Sep 20
    		$-0.72$-0.70-2.86%Miss-35.8%
    Jun 20
    		$-0.68$-0.60-13.33%Miss-41.7%
    Mar 20
    		$-0.45$-0.52+13.46%Beat+16.7%
    Dec 19
    		$-0.44$-0.55+20.00%Beat+13.7%
    Sep 19
    		$-0.53$-0.55+3.64%Beat-8.2%
    Jun 19
    		$-0.48$-0.56+14.29%Beat+12.7%
    Mar 19
    		$-0.54$-0.60+10.00%Beat+11.5%
    Dec 18
    		$-0.51$-0.52+1.92%Beat+40.0%
    Sep 18
    		$-0.49$-0.48-2.08%Miss+3.9%
    Jun 18
    		$-0.55$-0.57+3.51%Beat-5.8%
    Mar 18
    		$-0.61$-0.62+1.61%Beat+12.9%
    Dec 17
    		$-0.85$-0.47-80.85%Miss-16.4%
    Sep 17
    		$-0.51$-0.48-6.25%Miss-2.0%
    Jun 17
    		$-0.52$-0.54+3.70%Beat-
    Mar 17
    		$-0.70$-0.67-4.48%Miss-
    Dec 16
    		$-0.73$-0.61-19.67%Miss-
    Sep 16
    		$-0.50$-0.56+10.71%Beat-

    Key Metrics

    Valuation
    P/E Ratio-236.74EV/EBITDA-26.80x
    Price/FCF547.88xFCF Yield0.18%
    Profitability
    Profit Margin-7.11%Operating Margin-10.30%
    ROE-12.50%ROIC-10.70%
    Financial Health
    Debt/Equity0.06xInterest Coverage-70.90x
    Current Ratio3.00xQuick Ratio2.85x
    Trading Statistics
    Beta1.51Avg Volume1.45M
    52-Week High$343.1852-Week Low$157.43

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$328.34
    SMA 20$315.13
    SMA 50$285.92
    SMA 200$233.24
    EMA 10$325.73
    EMA 20$314.75
    EMA 50$287.66
    EMA 200$236.24

    MACD

    Line: 15.31Signal: 16.10Hist: -0.78

    ADX

    ADX: 41.1+DI: 28.7-DI: 17.5

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down8.0
    PSAR$342.83

    Bollinger Bands

    Upper Band$356.70
    Lower Band$273.56
    %B Position2638%(Upper)
    Band Width0.58

    RSI (14-Day)

    Neutral
    59.1

    Momentum Oscillators

    Stoch %K62.8
    Stoch %D78.5
    Williams %R-55.6
    ROC (10d)2.5%
    Momentum7.78
    CCI (20d)30.8
    MFI (14d)61.9

    Volatility Measures

    ATR (14d)$11.95(3.7%)
    StdDev (20d)20.78
    Hist Vol82.3%(High)

    Volume Flow

    VWAP$321.20
    OBV32.7M
    AD Line42.0M
    CMF (20d)0.169

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio0.7x
    VWMA (20d)$314.34

    Pivot Points

    R3$348.79
    R2$344.05
    R1$335.15
    Pivot Point$330.41
    S1$321.51
    S2$316.77
    S3$307.87

    Advanced Oscillators

    TSI34.11
    Ultimate Osc58.2
    KST193.78

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$752.75M$696.64M$665.50M$592.18M$546.60M$501.83M$476.06M$439.76M$413.35M$367.74M$311.11M$268.31M
    Cost of Revenue$267.56M$245.81M$220.07M$207.80M$200.00M$185.06M$176.42M$168.01M$170.18M$159.14M$151.25M$147.31M
    Gross Profit$485.19M$450.83M$445.43M$384.38M$346.60M$316.76M$299.64M$271.75M$243.17M$208.60M$159.86M$121.00M
    Operating Expenses$560.97M$545.74M$466.50M$481.96M$456.98M$396.24M$364.38M$311.08M$287.07M$282.92M$244.39M$231.98M
    R&D$228.07M$210.70M$175.19M$173.41M$146.43M$129.08M$129.46M$96.93M$89.11M$88.64M$82.96M$77.23M
    SG&A$327.20M$327.94M$291.30M$308.55M$310.55M$266.86M$234.92M$214.15M$197.97M$194.28M$161.43M$154.74M
    Operating Income$-75,792,000$-93,516,000$-22,786,000$-97,576,000$-110,372,000$-79,177,000$-64,740,000$-39,338,000$-43,902,000$-74,314,000$-84,536,000$-110,982,000
    Interest Income$0$0$10.45M$11.28M$0$0$10.91M$11.62M$10.46M$10.27M$9.84M$5.41M
    Interest Expense$890,000$892,000$990,000$1.04M$1.03M$1.00M$1.29M$3.14M$3.13M$3.12M$3.15M$3.25M
    Income Before Tax$-67,230,000$-84,808,000$-13,326,000$-87,337,000$-100,663,000$-66,763,000$-55,126,000$-30,862,000$-36,572,000$-67,171,000$-77,840,000$-108,828,000
    Income Tax Expense$-261,000$283,000$-60,584,000$207,000$275,000$173,000$-1,355,000$730,000$892,000$428,000$191,000$202,000
    Net Income$-66,969,000$-85,091,000$47.26M$-87,544,000$-100,938,000$-66,936,000$-53,771,000$-31,592,000$-37,464,000$-67,599,000$-78,031,000$-109,030,000
    EBITDA$-46,559,000$-62,299,000$-8,690,000$-87,271,000$-90,065,000$-56,212,000$-56,935,000$-30,882,000$-35,753,000$-67,383,000$-78,141,000$-103,194,000
    EBIT$-66,340,000$-83,916,000$-22,786,000$-97,576,000$-99,634,000$-65,758,000$-64,740,000$-39,338,000$-43,902,000$-74,314,000$-84,536,000$-110,982,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NTRA

    Government Contracts

    Gov Obligations (TTM)
    $427850
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    122.1%
    Active Awards
    6
    New Awards (TTM)
    3
    Avg Remaining Term
    8.8 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C25026C0095Department of Veterans AffairsDepartment of Veterans Affairs$157000Apr 7, 2026
    36C25626P0879Department of Veterans AffairsDepartment of Veterans Affairs$110000Jul 13, 2026
    36C24E26N0059Department of Veterans AffairsDepartment of Veterans Affairs$73500Mar 3, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Court Win Over Natera Patents Could Be A Game Changer For NeoGenomics’ (NEO) RaDaR ST

    NeoGenomics (NEO) recently secured a favorable North Carolina court ruling that invalidated key Natera patents, significantly reducing legal uncertainty around its RaDaR ST assay. This legal victory is expected to boost the competitive positioning of RaDaR ST and enhance NeoGenomics' overall oncology testing suite, especially when paired with their PanTracer liquid biopsy portfolio. Despite this win, investors should remain aware of competitive pressures and execution risks related to new product launches, while the company projects substantial revenue and earnings growth by 2029.

    Simply Wall Street•8/25/26•
    Neutral

    Natera Inc (NTRA) News, Articles, Events & Latest Updates

    This article provides a compilation of recent news, articles, and updates related to Natera Inc (NTRA). Key highlights include options becoming available for August 2027, billionaire Stanley Druckenmiller's significant investment in Natera, the company's strong past performance, and its support for the Kupando Trial in cancer monitoring. The article also mentions Natera's Q2 2026 earnings call transcript and a related piece on Tempus AI's FDA win.

    Stocktwits•8/25/26•
    Bullish

    Natera (NTRA) As Druckenmiller Backs Growth Story, Is The Valuation Already Priced In?

    Natera (NTRA) has gained significant investor attention after Stanley Druckenmiller's family office made it its largest holding, coinciding with strong revenue growth and improving free cash flow. While a popular valuation narrative suggests the stock is 18% overvalued at $332.03, projecting a fair value of $282.14 based on ambitious long-term assumptions, Simply Wall St's DCF model indicates it might be 45% undervalued with an estimated value of $604.78. Investors are urged to consider both the growth prospects and potential risks like clinical trial setbacks and high R&D spending.

    Simply Wall Street•8/24/26•
    Neutral

    NTRA|Natera Inc|Price:332.030|Chg%:+7.190

    This article provides a comprehensive stock analysis of Natera Inc (NTRA), highlighting its strong fundamentals, high growth potential, and "Buy" rating from multiple analysts. The company specializes in cell-free DNA and genetic testing for oncology, women’s health, and organ health, with an average revenue growth of 113.02% year-on-year over the past three years. Despite its strong performance, the technical analysis suggests the stock is currently trading sideways between support and resistance levels.

    TradingKey•8/22/26•
    Bullish

    Natera’s Oncology Push Has Wall Street Paying Up

    Natera (NASDAQ: NTRA), a molecular diagnostics company, has seen its revenue jump 38% year-on-year, driven by a strong push into oncology testing. The company's stock has surged by approximately 102% over the past year, attracting significant Wall Street interest despite its current high valuation and negative operating margins. While Natera faces risks related to high leverage, execution on margin expansion, and competitive pressures, its focus on oncology, particularly with its Signatera product, presents a strong growth story for investors willing to bet on future profitability.

    Finimize•8/22/26•
    Somewhat-Bullish

    Frequently Asked Questions About NTRA

    Does NTRA pay dividends?
    Natera Inc (NTRA) does not currently pay a regular dividend.
    What is NTRA's market cap?
    Natera Inc (NTRA) has a market capitalization of $47.03B with a current stock price of $321.96.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In